Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + olaparib + palbociclib
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
A combination therapy consisting of fulvestrant (a selective estrogen receptor degrader), olaparib (a PARP inhibitor), and palbociclib (a CDK4/6 inhibitor). This combination is being investigated for the treatment of BRCA1/2-associated hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. The therapy works by simultaneously targeting hormone signaling (fulvestrant), DNA repair mechanisms (olaparib), and cell cycle regulation (palbociclib).
- Other names
- HOPE combination therapy
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)ESR2 (ERβ)GPER1 (G protein-coupled estrogen receptor 1)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)PARP3 (Poly(adp-ribose) polymerase 3)
Beyond the preview
Go deeper on fulvestrant + olaparib + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + olaparib + palbociclib.